1. Trends and drivers of pharmaceutical expenditures from systemic anti-cancer therapy

   • Lars Børty
   • Rasmus F. Brøndum
   • Martin Bøgsted

   Original Paper 26 August 2022 Pages: 853 - 865

   

2. Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France

   • Manon Belhassen
   • Olivier Hanon
   • Nicolas Danchin

   Original Paper Open access 28 August 2022 Pages: 867 - 875

   

3. Completing the time trade-off with respondents who are older, in poorer health or with an immigrant background in an EQ-5D-5L valuation study

   • Tonya Moen Hansen
   • Knut Stavem
   • Kim Rand

   Original Paper Open access 02 September 2022 Pages: 877 - 884

   

4. Comparison of EQ-5D-5L and EORTC QLU-C10D utilities in gastric cancer patients

   • Chen-Wei Pan
   • Jun-Yi He
   • Pei Wang

   Original Paper 09 September 2022 Pages: 885 - 893

   

5. The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK

   • Adie Viljoen
   • Barrie Chubb
   • Stephen C. Bain

   Original Paper Open access 17 September 2022 Pages: 895 - 907

   

6. Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC⁴E trial in 15 European countries

   • Xiao Li
   • Joke Bilcke
   • ALIC4Etrial investigators

   Original Paper Open access 22 September 2022 Pages: 909 - 922

   

7. Do mobile hospital teams in residential aged care facilities increase health care efficiency: an evaluation of French residential care policy

   • Anne Penneau

   Original Paper 22 September 2022 Pages: 923 - 937

   

8. Using the EQ-5D-5L to investigate quality-of-life impacts of disease-modifying therapy policies for people with multiple sclerosis (MS) in New Zealand

   • Suzi Claflin
   • Julie A. Campbell
   • Bruce V. Taylor

   Original Paper Open access 23 September 2022 Pages: 939 - 950

   

9. The handling of missing data in trial-based economic evaluations: should data be multiply imputed prior to longitudinal linear mixed-model analyses?

   • Ângela Jornada Ben
   • Johanna M. van Dongen
   • Judith E. Bosmans

   Original Paper Open access 26 September 2022 Pages: 951 - 965

   

10. Willingness to pay for health gains from an international integrated early warning system for infectious disease outbreaks

    • Meg Perry-Duxbury
    • Sebastian Himmler
    • Werner Brouwer

    Original Paper Open access 28 September 2022 Pages: 967 - 986

    

11. The application of discrete choice experiments eliciting young peoples’ preferences for healthcare: a systematic literature review

    • Galina Williams
    • Irina Kinchin

    Original Paper Open access 28 September 2022 Pages: 987 - 998

    

12. Does competition improve hospital performance: a DEA based evaluation from the Netherlands

    • Peter Dohmen
    • Martin van Ineveld
    • Joris van de Klundert

    Original Paper Open access 04 October 2022 Pages: 999 - 1017